Register for our free email digests:
Latest From Shenzhen Hepalink Pharmaceutical Co. Ltd.
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.
UK biotech Kymab and its Kymouse platform has added $100m to its cash pile with a Series C financing led by Chinese investors. It plans to enter the clinic next year with its first antibody therapeutic for graft-versus-host disease (GvHD).
Ambitious and confident Chinese pharmaceutical buyers have begun to enter a new brave world of foreign M&A. However, this scenario can be littered with internal challenges and increasingly external scrutiny, less solid pre-deal asset identification and poor post-deal execution, all of which can damage their barely gained credibility, creating hurdles for future deals.
To promote both the development of innovative therapeutic antibodies from research originating in China and technology transfer, the Institute Pasteur of Shanghai and MRC Technology are collaborating to speed antibody R&D and scouting licensing opportunities with local pharmas, adding to a string of deals indicative of China’s increasing expertise and interest in the sector.
- Nanotechnology, Chips, etc.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Medical Devices
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Rheonix Inc.
- Senior Management
Tony Eisenhut, Pres. & CEO
Peng Zhou, PhD, SVP, R&D & CSO
Richard A Montagna, SVP, Corp. Bus. Dev. & Scientific Affairs
- Contact Info
Phone: (607) 257-1242
22 Thornwood Dr.
Ithaca, NY 14850
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.